Cognition Therapeutics Reports P-II Study (SEQUEL) Results of CT1812 for Mild-to-Moderate Alzheimer’s Disease in Netherlands
Shots:
- The P-II study (SEQUEL) met its 1EPs (safety and tolerability) as measured via quantitative electroencephalogram (qEEG). The study received grant from the National Institute on Aging (R01AG058710)
- This study evaluated brain wave changes over 4wks. of treatment and participants (n=16) experienced a numerical reduction in relative theta power vs PBO in frontal, central, temporal, and posterior regions with a statistically significant change in the central region
- The AECc analysis of the qEEG also demonstrated nominally statistically significantly greater connectivity between brain regions. The data from canonical biomarkers and proteomics from fluid samples will be presented at an upcoming medical meeting
Ref: Ocugen | Image: Ocugen
Related News:- Ocugen’s NeoCart Receives the US FDA Regenerative Medicine Advanced Therapy Recognition for the Treatment of Knee Injury in Adults
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
